Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

• Sponsor: Pfizer (Industry)
• Overall Status: Recruiting
• CT.gov ID: NCT04585815
• Collaborator: (none)
• Enrollment: 375
• Locations: 110
• Arms: 2
• Anticipated Duration (Months): 61.3
• Patients Per Site: 3.4
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study.

Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination.

Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated.

Sub-study B remains active, enrolment is ongoing.

Condition or Disease	Intervention/Treatment	Phase
Carcinoma, Non-Small-Cell Lung	Drug: Sasanlimab Prefilled syringe; Drug: Encorafenib; Drug: Binimetinib; Drug: Sasanlimab; Drug: Axitinib; Drug: SEA-TGT	Phase 1/Phase 2

Detailed Description

Landscape 1011 is a clinical research study for people with advanced (stage 3b or 4) non-small cell lung cancer (NSCLC). The purpose of this study is to learn if the study medicine (sasanlimab, a type of immunotherapy) along with other study medicines is safe and effective in people with non-small cell lung cancer that has spread outside of the lungs. There are currently two sub-studies using different types of medicines. People in the first sub-study will receive sasanlimab as a subcutaneous (under the skin) injection at the study clinic every 4 weeks. Additionally, they will take targeted cancer therapies encorafenib by mouth once a day and binimetinib by mouth twice a day at home.

People in the second sub-study will receive the study medicine sasanlimab as a subcutaneous (under the skin) injection at the study clinic every 3 weeks and will also receive SEA-TGT (an immunotherapy) by infusion every three weeks.

Additionally, they will take axitinib (a targeted therapy) by mouth twice a day at home.

In addition to taking the study drugs, participants in the sub-studies will be asked to visit the clinic for health checks. These include health questions, physical examinations, blood and urine samples, and imaging scans. These assessments help the study doctor and team to monitor the participants' safety and well-being, and to see how their cancer is responding to the treatment. Participants will continue in the study until the cancer is no longer responding to the study medicine.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 375 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)
• Actual Study Start Date: Nov 10, 2020
• Anticipated Primary Completion Date: Nov 27, 2024
• Anticipated Study Completion Date: Dec 20, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Sub-Study A Sasanlimab will be administered subcutaneously. Encorafenib & binimetinib will be administered orally. Treatments will be administered until progressive disease, unacceptable AE, participant withdraws, or study is terminated.	Drug: Sasanlimab Prefilled syringe; prefilled syringe; Drug: Encorafenib; capsules; Drug: Binimetinib; tablets
Experimental: Sub-Study B Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease, unacceptable AE, patient withdraws, or study is terminated.	Drug: Sasanlimab; solution supplied in vials; Drug: Axitinib; tablets; Drug: SEA-TGT; solution in vials

Outcome Measures

Primary Outcome Measures

1. Percentage of participants with Dose-limiting toxicities (DLT) [First dose (Cycle 1 Day 1) to end of first treatment cycle (about 21-28 days)]

   Phase 1 Primary Outcome: DLTs are a predefined set of observed adverse events that are at least possibly related to at least 1 of the investigational agents.

2. Durable Objective Response Rate - Percentage of Participants With Objective Response [First dose (Cycle 1 Day 1) to End of Study Treatment (up to about 24 months); each cycle is about 28 days]

   Sub-Study A only, Phase 2 only: Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) lasting for at lease 10 months, according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

3. Objective Response Rate-Percentage of Participants with Objective Response [First dose (Cycle 1 Day 1) to End of Treatment (up to about 24 months); each cycle is about 21 days]

   Sub-Study B only, Phase 2 only: Percentage of participants with CR or PR, according to RECIST v1.1.

Secondary Outcome Measures

1. Number of participants with Treatment-Emergent Adverse Events [First dose (Cycle 1 Day 1) to 30 days after last dose (up to about 24 months); each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

   Phase 1b and Phase 2

2. Percentage of participants with Treatment-Emergent Adverse Events [First dose (Cycle 1 Day 1) to 30 days after last dose (up to about 24 months); each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

   Phase 1b and Phase 2

3. Number of Participants with Treatment-Emergent Laboratory Abnormalities [First dose (Cycle 1 Day 1) to 30 days after last dose (up to about 24 months); each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

   Phase 1b and Phase 2

4. Percentage of Participants with Treatment-Emergent Laboratory Abnormalities [First dose (Cycle 1 Day 1) to 30 days after last dose (up to about 24 months); each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

   Phase 1b and Phase 2

5. Durable Objective Response Rate - Percentage of Participants With Objective Response [First dose (Cycle 1 Day 1) to End of Study Treatment (up to about 24 months); each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

   Sub-Study A only, Phase 1b only: Percentage of participants with confirmed CR or PR lasting for at lease 10 months, according to RECIST v1.1

6. Objective Response Rate-Percentage of Participants with Objective Response [First dose (Cycle 1 Day 1) to End of Treatment (up to about 24 months); each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

   Sub-study A Phase 1 and Phase 2, Sub-Study B, Phase 1 only: Percentage of participants with CR or PR, according to RECIST v1.1.

7. Duration of Response (DR) [First objective response to progressive disease or death (up to about 24 months); each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

   Phase 2 only

8. Time to Tumor Response (TTR) [First dose (Cycle 1 Day 1) up to first objective response. Each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

   Phase 2 only: The time from first dose to first documentation of objective tumor response of CR or PR.

9. Progression-Free Survival (PFS) [First dose (Cycle 1 Day 1) to progressive disease or death (up to about 24 months). Each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

   Phase 2 only

10. Overall Survival [First dose (Cycle 1 Day 1) to death (up to about 40 months); each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

    Phase 2 only

11. Incidence of Anti-Drug Antibody (ADA) for the study drugs [First dose (Cycle 1 Day 1) to End of Treatment (up to about 24 months); each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B]

    Phase 1b and Phase 2

12. Neutralizing antibody (NAb) titers for sasanlimab [First dose (Cycle 1 Day 1) to End of Treatment (up to about 24 months); each cycle is about 28 days]

    Sub-Study A only, Phase 1b and Phase 2

13. Association between Objective Response and PD-L1 expression at baseline [First dose (Cycle 1 Day 1) to End of Study Treatment (up to about 24 months); each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B.]

    Phase 2 only

14. PK Parameter Ctrough [First dose (Cycle 1 Day 1) to End of Treatment (up to about 24 months). About 1-3 draws per Cycle for the first year, and then every 6 cycles until EOT. Each cycle is about 28 days in Sub-Study A and 21 days in Sub-Study B.]

    Phase 1b and Phase 2: Ctrough of the study drugs when administered in combination, as data permit.

15. European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) Score [First dose (Cycle 1 Day 1) to End of Study Treatment (up to about 24 months); each cycle is about 28 days]

    Sub-Study A only, Phase 2 only; EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

16. European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) Score [First dose (Cycle 1 Day 1) to End of Study Treatment (up to about 24 months); each cycle is about 28 days]

    Sub-Study A only, Phase 2 only; QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.

17. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) Score [First dose (Cycle 1 Day 1) to End of Study Treatment (up to about 24 months); each cycle is about 28 days]

    Sub-Study A only, Phase 2 only; EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

18. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) Score [First dose (Cycle 1 Day 1) to End of Study Treatment (up to about 24 months); each cycle is about 28 days]

    Sub-Study A only, Phase 2 only; QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria Umbrella Phase 1b & 2:

• Histologically or cytologically confirmed locally advanced/metastatic (Stage IIIB-IV) NSCLC.

• At least one measurable lesion per RECIST v1.1 at Screening.

• ECOG Performance Status 0 or 1.

• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.

• Adequate hepatic, renal, and bone marrow function.

Additional Inclusion Criteria for Sub-Study A Phase 1b &2:

-BRAFV600E mutation in tumor tissue or plasma as determined by a local laboratory PCR or NGS assay and documented in a local pathology report.

Additional Inclusion Criteria for Sub-Study A Phase 1b only:

-Any line of therapy for locally advanced/metastatic NSCLC.

Additional Inclusion Criteria for Sub-Study A Phase 2 only:

-Previously untreated for locally advanced/metastatic NSCLC

Additional Inclusion Criteria for Sub-Study B Phase 1b only::

-Any line of therapy for locally advanced/metastatic NSCLC.

Additional Inclusion Criteria for Sub-Study B Phase 2 only:

• Previously untreated for locally advanced/metastatic NSCLC (Arms B1 & B2), or

• One or 2 prior lines of therapy for advanced/metastatic NSCLC (Arm B3), including immune checkpoint inhibitor treatment + chemotherapy, and have progressed during or after that therapy.

• PD-L1 TPS ≥1%

Exclusion Criteria Umbrella Phase 1b &2:

• Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent.

• Active non-infectious pneumonitis, pulmonary fibrosis, or known history of immune-mediated pneumonitis.

• Active infection requiring systemic therapy.

• Clinically significant cardiovascular disease.

• Other malignancy within 2 years of first dose, with exceptions.

• Symptomatic brain metastasis, with exceptions.

Additional Exclusion Criteria for Sub-Study A Phase 1b&2:

• EGFR mutation, ALK fusion oncogene, or ROS1 rearrangement.

• Prior treatment with any BRAF inhibitor or MEK inhibitor.

Additional Exclusion Criteria for Sub-Study A Phase 2 only:

-Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.

Additional Exclusion Criteria for Sub-Study B Phase 1b&2:

-Documentation of any tumor-driving molecular alteration (eg, BRAF, EGFR, ALK)

Additional Exclusion Criteria for Sub-Study B Phase 2 only:

• Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.(Arms B1 & B2)

• Confirmed progressive disease on 1st or 2nd imaging tumor assessment after initiation of therapy for advanced/metastatic NSCLC.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	City of Hope Investigational Drug Services (IDS)	Duarte	California	United States	91010
2	City of Hope	Duarte	California	United States	91010
3	UCSD Medical Center - Encinitas	Encinitas	California	United States	92024
4	California Cancer Associates for Research and Excellence, Inc (cCARE)	Fresno	California	United States	93720
5	The Oncology Institute of Hope and Innovation	Glendale	California	United States	91204
6	UC San Diego Moores Cancer Center - Investigational Drug Services	La Jolla	California	United States	92037-0845
7	Koman Family Outpatient Pavilion	La Jolla	California	United States	92037
8	Sulpizio Cardiovascular Center at UC San Diego Health	La Jolla	California	United States	92037
9	UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)	La Jolla	California	United States	92037
10	UCSD Perlman Medical Offices	La Jolla	California	United States	92037
11	UC San Diego Moores Cancer Center	La Jolla	California	United States	92093
12	The Oncology Institute of Hope and Innovation	Long Beach	California	United States	90805
13	The Oncology Institute of Hope and Innovation	Los Angeles	California	United States	90015
14	Keck Hospital of USC	Los Angeles	California	United States	90033
15	Keck Medicine of USC - USC Roski Eye Institute	Los Angeles	California	United States	90033
16	LAC + USC Medical Center	Los Angeles	California	United States	90033
17	USC/Norris Comprehensive Cancer Center	Los Angeles	California	United States	90033
18	Keck Medical Center of USC Pasadena	Pasadena	California	United States	91105
19	UC San Diego Medical Center - Hillcrest	San Diego	California	United States	92103
20	The Oncology Institute of Hope and Innovation	Santa Ana	California	United States	92705
21	UCSD Medical Center - Vista	Vista	California	United States	92081
22	The Oncology Institute of Hope and Innovation	Whittier	California	United States	90602
23	UCHealth Sue Anschutz-Rodgers Eye Center	Aurora	Colorado	United States	80045
24	University of Colorado Cancer Center	Aurora	Colorado	United States	80045
25	University of Colorado Denver CTO/CTRC	Aurora	Colorado	United States	80045
26	University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)	Aurora	Colorado	United States	80045
27	University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)	Aurora	Colorado	United States	80045
28	University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)	Aurora	Colorado	United States	80045
29	UCHealth Memorial Hospital Central	Colorado Springs	Colorado	United States	80909
30	UCHealth Memorial Hospital North	Colorado Springs	Colorado	United States	80920
31	Florida Cancer Specialists	Altamonte Springs	Florida	United States	32701
32	Florida Cancer Specialists	Bonita Springs	Florida	United States	34135
33	Florida Cancer Specialists	Bradenton	Florida	United States	34211
34	Florida Cancer Specialists	Brandon	Florida	United States	33511
35	Florida Cancer Specialists	Cape Coral	Florida	United States	33909
36	AdventHealth Celebration Infusion Center	Celebration	Florida	United States	34747
37	AdventHealth Medical Group Oncology Research at Celebration	Celebration	Florida	United States	34747
38	Florida Cancer Specialists	Clearwater	Florida	United States	33761
39	Florida Cancer Specialists	Fort Myers	Florida	United States	33901
40	Florida Cancer Specialists	Fort Myers	Florida	United States	33905
41	Florida Cancer Specialists	Fort Myers	Florida	United States	33908
42	Florida Cancer Specialists	Gainesville	Florida	United States	32605
43	Florida Cancer Specialists	Largo	Florida	United States	33770
44	Florida Cancer Specialists	Lecanto	Florida	United States	34461
45	Florida Cancer Specialists	Naples	Florida	United States	34102
46	Florida Cancer Specialists	Ocala	Florida	United States	34474
47	Florida Cancer Specialists	Orange City	Florida	United States	32763
48	Advent Health Orlando - Investigational Drug Services	Orlando	Florida	United States	32804
49	AdventHealth Hematology and Oncology	Orlando	Florida	United States	32804
50	AdventHealth Orlando Infusion Center	Orlando	Florida	United States	32804
51	Florida Cancer Specialists	Orlando	Florida	United States	32806
52	Florida Cancer Specialists	Port Charlotte	Florida	United States	33980
53	Florida Cancer Specialists	Saint Petersburg	Florida	United States	33705
54	Florida Cancer Specialists	Sarasota	Florida	United States	34232
55	Florida Cancer Specialists	Sarasota	Florida	United States	34236
56	Florida Cancer Specialists	Spring Hill	Florida	United States	34608
57	Florida Cancer Specialists	Tampa	Florida	United States	33607
58	Moffitt Cancer Center	Tampa	Florida	United States	33612
59	Florida Cancer Specialists	Tavares	Florida	United States	32778
60	Florida Cancer Specialists	The Villages	Florida	United States	32159
61	Florida Cancer Specialists	Trinity	Florida	United States	34655
62	Florida Cancer Specialists	Venice	Florida	United States	34285
63	Florida Cancer Specialists	Venice	Florida	United States	34292
64	Florida Cancer Specialists	Winter Park	Florida	United States	32792
65	University of Maryland Greenebaum Comprehensive Cancer Center	Baltimore	Maryland	United States	21201
66	University of Maryland Medical Center -IDS Pharmacy	Baltimore	Maryland	United States	21201
67	Massachusetts General Hospital	Boston	Massachusetts	United States	02114
68	Ophthalmic Consultants of Boston Inc (OCB)	Boston	Massachusetts	United States	02114
69	Brigham and Women's Hospital (BWH)	Boston	Massachusetts	United States	02215
70	Dana-Farber Cancer Institute	Boston	Massachusetts	United States	02215
71	Dana-Farber Cancer Institute - Chestnut Hill	Newton	Massachusetts	United States	02459
72	Henry Ford Medical Center - Fairlane	Dearborn	Michigan	United States	48126
73	Henry Ford Hospital	Detroit	Michigan	United States	48202
74	Henry Ford Medical Center - Columbus	Novi	Michigan	United States	48377
75	Atlantic Health System / Morristown Medical Center	Morristown	New Jersey	United States	07962
76	Morristown Medical Center	Morristown	New Jersey	United States	07962
77	Medical Diagnostic Associates	Summit	New Jersey	United States	07901
78	Overlook Medical Center	Summit	New Jersey	United States	07901
79	Icahn School of Medicine at Mount Sinai	New York	New York	United States	10029
80	Mount Sinai Hospital Pharmacy	New York	New York	United States	10029
81	Tennessee Oncology PLLC	Dickson	Tennessee	United States	37055
82	Tennessee Oncology PLLC	Franklin	Tennessee	United States	37067
83	Tennessee Oncology PLLC	Gallatin	Tennessee	United States	37066
84	Tennessee Oncology PLLC	Hendersonville	Tennessee	United States	37075
85	Tennessee Oncology PLLC	Hermitage	Tennessee	United States	37076
86	Tennessee Oncology PLLC	Lebanon	Tennessee	United States	37090
87	Tennessee Oncology PLLC	Murfreesboro	Tennessee	United States	37129
88	Sarah Cannon Research Institute - Pharmacy	Nashville	Tennessee	United States	37203
89	Tennessee Oncology PLLC	Nashville	Tennessee	United States	37203
90	Tennessee Oncology PLLC	Nashville	Tennessee	United States	37205
91	Tennessee Oncology PLLC	Nashville	Tennessee	United States	37207
92	Tennessee Oncology PLLC	Nashville	Tennessee	United States	37211
93	Tennessee Oncology PLLC	Shelbyville	Tennessee	United States	37160
94	Tennessee Oncology PLLC	Smyrna	Tennessee	United States	37167
95	Chris O'Brien Lifehouse	Camperdown	New South Wales	Australia	2050
96	Concord Hospital	Concord	New South Wales	Australia	2139
97	GenesisCare North Shore	St Leonards	New South Wales	Australia	2065
98	North Shore Radiology and Nuclear Medicine	St Leonards	New South Wales	Australia	2065
99	Austin Health	Heidelberg	Victoria	Australia	3084
100	Antwerp University Hospital	Edegem	Antwerpen	Belgium	2650
101	UZ Gent	Gent		Belgium	9000
102	Princess Margaret Cancer Centre - University Health Network	Toronto	Ontario	Canada	M5G 2M9
103	Chung Shan Medical University Hospital	Taichung		Taiwan	40201
104	National Taiwan University Hospital	Taipei City		Taiwan	100
105	Koo Foundation Sun Yat -Sen Cancer Center	Taipei City		Taiwan	112
106	National Taiwan University Hospital	Taipei		Taiwan	10002
107	Koo Foundation Sun Yat-Sen Cancer Center	Taipei		Taiwan	112
108	Sarah Cannon Research Institute UK	London		United Kingdom	W1G 6AD
109	Royal Victoria Infirmary	Newcastle upon Tyne		United Kingdom	NE1 4LP
110	Sir Bobby Robson Cancer Trials Research Centre	Newcastle upon Tyne		United Kingdom	NE7 7DN

Sponsors and Collaborators

• Pfizer

Investigators

• Study Director: Pfizer CT.gov Call Center, Pfizer

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• To obtain contact information for a study center near you, click here.

Publications

None provided.

• Responsible Party: Pfizer
• ClinicalTrials.gov Identifier: NCT04585815
• Other Study ID Numbers: B8011011; 2020-002829-28
• First Posted: Oct 14, 2020
• Last Update Posted: Aug 22, 2022
• Last Verified: Aug 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Pfizer: Non-Small-Cell Lung Carcinoma; NSCLC; non small cell lung cancer; non-small cell lung cancer; BRAF mutation; BRAF V600e; BRAF; B-RAF NSCLC; lung cancer; immunotherapy; sasanlimab; encorafenib; binimetinib; axitinib; SEA-TGT; TIGIT; locally advanced; metastatic; ECOG 0; ECOG 1; Stage 3B; Stage IV; previously untreated; second-line therapy; first-line therapy
• Additional relevant MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Axitinib

Study Results

No Results Posted as of Aug 22, 2022